Karnataka High Court: Judicial Powers Cannot be Exercised by Conciliators in Lok Adalats  ||  Mad. HC: Registering Authorities Not Empowered to Cancel Sale Deed Through Summary Proceedings  ||  Telangana High Court: Section 18 UAPA is Penal in Nature, Needs to be Proved by Prosecution  ||  Karnataka High Court: Rights of Adopted Child of Indian Parents Cannot be Left Marooned  ||  All. HC: No Authority to Additional Chief Medical Officer to File Complaint Under PCPNDT Act  ||  Kar. HC: Cannot Prosecute Second Spouse or Their Family for Bigamy Under Section 494 IPC  ||  Calcutta High Court: Person Seeking to Contest Elections is Deemed Public Interest  ||  Mad HC: In Absence of Prohibitory Order u/s 144 CrPC People Assembling and Demonstrating Not Offence  ||  Bom. HC: Legal Action to be Taken Against Doctor for Gross Negligence in Conducting Postmortem  ||  Bom. HC: Husband Directed to Pay Wife Compensation of Rs. 3 Crore for DV & Calling Her ‘Second-Hand’    

CCI approves acquisition of Micro Life Sciences Private Limited by South Elm Investments B.V.- (Press Information Bureau) (16 Mar 2022)

MANU/PIBU/0878/2022

MRTP/ Competition Laws

The Competition Commission of India (CCI) approves acquisition of Micro Life Sciences Private Limited by South Elm Investments B.V.

The proposed combination pertains to the proposed acquisition of minority stake in Micro Life Sciences Private Limited (Micro Life/ Target) by South Elm Investments B.V. (SEI/ Acquirer).

SEI is an investment holding company incorporated under the laws of Netherlands. The shareholders of SEI are certain private equity funds managed by Warburg Pincus LLC.

Target is a company incorporated in India, which is primarily engaged in the following business activities in India along with subsidiaries: manufacture and sale of (a) medical devices in various categories such as stents, Percutaneous Transluminal Coronary Angioplasty catheters, heart valves, orthopedic implants, and endo-surgery products (such as sutures, staplers, meshes and intrauterine devices); (b) in-vitro diagnostics analyzers and reagents; and (c) over the counter (OTC) products like products COVID self-test kits and pregnancy test kits, in India. The Target (through its subsidiaries) is engaged in the B2C sale of certain specialized medical devices (such as surgical robots and ultrasonic energy devices) to hospitals and has research and development (R&D) facilities for in-vitro diagnostic, orthopedic, endo-surgery and cardiovascular solutions.

Tags : ACQUISITION   APPROVAL   MINORITY STAKE  

Share :        

Disclaimer | Copyright 2024 - All Rights Reserved